Practice Pearls

What can we help you find?
Goals of Therapy
An introduction to practice pearl #1 with identifying severity of disease, and determining goals of therapy.
Prophylaxis
Experts identify patients considered for prophylaxis care and discuss determining individualized regimens.
Hemophilia
Luigi Brunetti, PharmD, MPH, BCPS, BCGP, associate professor, Rutgers University Ernest Mario School of Pharmacy, and Robert Wood Johnson University Hospital, Somerset, New Jersey, moderates a discussion on best practices for hemophilia treatment. He is joined by Robert F Sidonio, Jr, MD, medical director of Hemophilia, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, and assistant professor of pediatrics,Emory University School of Medicine, Atlanta, Georgia; and Giles W. Slocum, Pharm.D., BCCCP, clinical pharmacy specialist, Emergency Medicine, Rush University Medical Center in Illinois.

 
Peter Salgo, MD will lead a panel of experts to identify the new, curative treatment options for hepatitis C, and restrictions to access.
Future Implications of Subcutaneous Dosing
Concluding the discussion, the panel considers future directions for subcutaneous dosing.
Financial Benefit of Subcutaneous Dosing
Experts move on to discuss the various levels of financial benefit with subcutaneous dosing.
Calculating Dose for SQ Formulations
Practical considerations regarding the dosing of subcutaneous formulations
Pharmacokinetic Differences with SQ Dosing
Key opinion leaders break down the pharmacokinetic properties of subcutaneous formulations.
Adding SQ Dosing to the Formulary
Experts discuss who and what is involved in adding subcutaneous formulations to the formulary.
Benefits of SQ Dosing for Patients
A panel of experts reviews the benefits of subcutaneous dosing from the patient perspective.
Selecting SQ Formulation for a Patient
Factors that inform the decision to stratify patients to subcutaneous formulations.
Addressing Reluctance to Use SQ Dosing
Potential clinical and financial causes for hesitation in the transition to subcutaneous dosing are addressed.